CEACAM-1
CEACAM-1 Molekülinformation
| Englischer Name | Carcinoembryonic antigen related cell adhesion molecule 1 | Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 1 | Target-Alias | CEACAM1，Biliary glycoprotein 1，BGP，CD66a，Carcinoembryonic Antigen Related Cell Adhesion Molecule 1，CD66a Antigen，BGP1，Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1，Antigen CD66，BGP-1，BGPI，CEA Cell Adhesion Molecule 1，Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (Biliary Glycoprotein) |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical | ||
| Englischer Name | Carcinoembryonic antigen related cell adhesion molecule 1 |
| Target-Alias | CEACAM1，Biliary glycoprotein 1，BGP，CD66a，Carcinoembryonic Antigen Related Cell Adhesion Molecule 1，CD66a Antigen，BGP1，Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1，Antigen CD66，BGP-1，BGPI，CEA Cell Adhesion Molecule 1，Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (Biliary Glycoprotein) |
| Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 1 |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical |
CEACAM-1 Produktliste
- Attribut
Protein (3)
- Produktbibliothek
Online (3)
- Spezies
Human (2)Cynomolgus (1)
- Etikett
His Tag (2)His Tag & Avi Tag (1)
- Marker
Unconjugated (2)Biotin-labeled (1)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
 Human | HEK293 | Human CEACAM-1 / CD66a Protein, His Tag, low endotoxin |  |  |  |  In den Warenkorb legen | |
| Human | HEK293 | Biotinylated Human CEACAM-1 / CD66a Protein, Avitag™,His Tag |  | | | In den Warenkorb legen | |
 Cynomolgus | HEK293 | Cynomolgus CEACAM-1 / CD66a Protein, His Tag |  | | In den Warenkorb legen |
Gesamtmenge3
- 1
CEACAM-1 Molekülhintergrund
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is also known as Biliary glycoprotein 1 (BGP1), CD66a, which belongs to the immunoglobulin superfamily or CEA family. CEACAM1 /CD66a contains three Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. CEACAM1 /CD66a was described as an adhesion molecule mediating cell adhesion via both homophilic and heterophilic manners, and was detected on leukocytes, epithelia, and endothelia. Studies have revealed that CEACAM1 / BGP-1 performs actions in multiple cellular processes including tissue differentiation, angiogenesis, apoptosis, metastasis, as well as the modulation of innate and adaptive immune responses.
CEACAM-1 Molekülalias
CEACAM1,CD66a,BGP,BGP1,BGPI
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| CM-24 | CM-24 (MK-6018); MK-6018; CM-24 | Phase 2 Clinical | Merck Sharp & Dohme Corp | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Thyroid Cancer, Papillary; Urinary Bladder Neoplasms | Details |
- Molekülinformation
- Produktliste
- Klinische Arzneimittelinformation